About NoviSci
NoviSci is a company based in Durham (United States) founded in 2016 by M Alan Brookhart was acquired by Target RWE in January 2021. NoviSci offers products and services including Training Modules and Slide Presentations. NoviSci operates in a competitive market with competitors including Inato, goBalto, Acme Clinical Trials, Clinata and Dementias Platform, among others.
- Headquarter Durham, United States
- Founders M Alan Brookhart
- SectorsHealthcare
- Website novisci.com
- Social LinkedIn
- Acquired by Target RWE (Jan 2021)
- Legal Name United Therapeutics Corporation
- Investors
- Acquired byTarget RWE
(Jan 2021)
Products & Services of NoviSci
NoviSci offers a comprehensive portfolio of products and services, including Training Modules and Slide Presentations.
Interactive modules for pharmacy partner learning.
Guided slides on pharmacy services and tools.
Investors in NoviSci
NoviSci has secured backing from 1 investor. Prominent investors backing the company include Target RWE.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Marketing services to the pharmaceutical industry are provided. | 2017 | targetrwe.com | Durham, United States |
Investor details for NoviSci
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of NoviSci
14 people are tracked at NoviSci (9 in leadership, 4 in board & advisors, 1 in team).
| Name | Role | Group |
|---|---|---|
M Alan Brookhart | Co-Founder | Leadership |
Michael W. Fried | Co-Founder & Chief Medical Officer | Leadership |
Joy Peter | VP, Evidence Solutions | Leadership |
Tara Bridgeman | Senior Director, Human Resources | Leadership |
Julie Mallory Crawford | VP, RWE & Strategic Partnerships | Leadership |
Matt Roth | VP, Finance | Leadership |
Alan Brookhart | Chief Scientific Officer | Leadership |
Rob Sullivan | Chief Data & Analytics Officer | Leadership |
Nathan Nussbaum | Head Of Data Innovation | Leadership |
Meg Powell | Co-Founder & Chair | Board & advisors |
Eric Edell | Board Member | Board & advisors |
Andrew Von Eschenbach | Senior Advisor | Board & advisors |
Franz Humer | Senior Advisor | Board & advisors |
Sonia Li | Board Observer | Team |
Complete people profiles for NoviSci
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of NoviSci
2 dated milestones of NoviSci across 5 years, from founding to its latest funding, stage changes and deals.
- Founded NoviSci is founded.
- Exit Acquired by Target RWE.
Competitors of NoviSci
NoviSci operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Inato, goBalto, Acme Clinical Trials, Clinata and Dementias Platform, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| inato.com | 2016 | Paris, France | $35.52M | – | AI-based patient recruitment platform | |
| gobalto.com | 2008 | San Francisco, United States | $38.25M | 66 | Cloud-based SaaS solutions for clinical trial startup are offered. | |
| aclinicaltrials.com | 2017 | San Jose, United States | – | – | Provides an online database of clinical trial studies for researchers. | |
| clinata.com | 2012 | Dallas, United States | $100,000 | – | Online Clinical Research Marketplace | |
| dementiasplatform.uk | 2014 | Oxford, United Kingdom | – | – | Platform for dementia research, data access, and clinical trials collaboration. | |
| altavoice.com | 2004 | San Mateo, United States | – | – | Patient Insight Network (PIN) helping drug developers find better treatments for diseases | |
| doctorpenguin.com | 2019 | United States | – | – | Provides an online platform with comprehensive health information for COVID-19. | |
| quosa.com | 2001 | Waltham, United States | – | – | Scientific Literature Management Software by Elsevier |
Detailed competitors of NoviSci
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of NoviSci
The website of NoviSci (novisci.com) receives about 2.4K visits a month.
- Monthly visits2.4K
▼ 8.1% vs previous month
Latest news on Novisci
Complete news archive for NoviSci
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to NoviSci
10 companies that operate in the same segment as NoviSci (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | – | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about NoviSci
NoviSci was founded in 2016.
NoviSci is headquartered in Durham, United States. It is registered at Durham, North Carolina, United States.
NoviSci was founded in 2016 and is headquartered in Durham, United States. An online platform is operated by the company within the scientific research sector, where tools are supplied to assist professionals and researchers in sourcing, visualizing, and analyzing health data. Epidemiological methods and scientific principles are integrated into the platforms functionalities to support data-driven insights.
NoviSci offers Training Modules and Slide Presentations.
NoviSci has 1 investor. Key investors include Target RWE.
NoviSci operates through United Therapeutics Corporation.
Yes. NoviSci was acquired by Target RWE in January 2021.